DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: INCRELEX

Summary for Tradename: INCRELEX

Patents:3
Applicants:1
NDAs:1
Suppliers: see list1
drug
patent expirations by year for
 INCRELEX

Clinical Trials for: INCRELEX

IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex
Status: Active, not recruiting Condition: Primary Insulin-like Growth Factor-1 Deficiency

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency
Status: Completed Condition: Insulin-like Growth Factor-1 Deficiency

European Increlex® (Mecasermin [rDNA Origin] Injection) Growth Forum Database - IGFD Registry
Status: Recruiting Condition: IGF1 Deficiency

Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection)
Status: Completed Condition: Rett Syndrome

Long-Term Treatment With rhIGF-1 in GHIS
Status: Active, not recruiting Condition: Growth Hormone Insensitivity Syndrome

Effect of Increlex® on Children With Crohn Disease
Status: Recruiting Condition: Crohn Disease

Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa
Status: Completed Condition: Disorder of Bone Density and Structure, Unspecified

Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency
Status: Completed Condition: Insulin-Like Growth Factor-1 Deficiency; Growth Disorders

Treatment of Rett Syndrome With Recombinant Human IGF-1
Status: Recruiting Condition: Rett Syndrome

Increlex Treatment of Children With Chronic Liver Disease and Short Stature
Status: Not yet recruiting Condition: Growth Failure; Chronic Liver Disease

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ipsen Inc
INCRELEX
mecasermin recombinant
INJECTABLE;SUBCUTANEOUS021839Aug 30, 2005RXYes5,681,814<disabled>Y<disabled>
Ipsen Inc
INCRELEX
mecasermin recombinant
INJECTABLE;SUBCUTANEOUS021839Aug 30, 2005RXYes5,824,642<disabled><disabled>
Ipsen Inc
INCRELEX
mecasermin recombinant
INJECTABLE;SUBCUTANEOUS021839Aug 30, 2005RXYes6,207,640<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc